Healthcare / Drug Manufacturers - Specialty & GenericKSE
$5440.00
-70.00 (-1.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-39.6B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$150.8B
P/E
17.4x
↓EV/EBITDA
7.9x
↓ROE
2.3%
↑Gross Margin
44.0%
↓Debt/Equity
0.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.4%
FCF CAGR
—
FCF margin
-8.0%
FCF / Net income
-4.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $496.39B · net income $8.69B · FCF $-39.60B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $496.39B | $496.39B | $464.87B | $361.11B | $340.43B |
| Net Income | $8.69B | $8.69B | $5.56B | $27.44B | $20.38B |
| EBITDA | $32.48B | $32.48B | $28.72B | $51.16B | $35.96B |
| EPS | 313.00 | 313.00 | 201.00 | 991.00 | 736.00 |
| Gross Margin | 44.0% | 44.0% | 46.1% | 52.7% | 53.2% |
| Operating Margin | 0.1% | 0.1% | 2.9% | 5.2% | 8.8% |
| Net Margin | 1.7% | 1.7% | 1.2% | 7.6% | 6.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.31 | 0.31 | 0.26 | 0.13 | 0.02 |
| Current Ratio | 4.09 | 4.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-39.60B | $-39.60B | $-78.07B | $2.82B | $9.13B |
| Returns | |||||
| ROE | 2.3% | 2.3% | 1.5% | 7.4% | 5.6% |
| Valuation | |||||
| P/E | 17.38 | 17.38 | 31.49 | 10.57 | 12.79 |
| EV/EBITDA | 7.88 | 7.88 | 8.58 | 5.17 | 6.48 |
| P/B | 0.40 | 0.40 | 0.47 | 0.78 | 0.72 |
| Growth & Yield | |||||
| Revenue Growth | 6.8% | 6.8% | 28.7% | 6.1% | — |
| EPS Growth | 55.7% | 55.7% | -79.7% | 34.6% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.5%
EPS terminal req.
$482.71
Spread vs growth
40.2%
5Y implied EPS CAGR
13.3%
EPS terminal req.
$584.08
Spread vs growth
42.4%
10Y implied EPS CAGR
11.6%
EPS terminal req.
$940.66
Spread vs growth
44.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.9%
Start / end P/E
31.1x → 17.4x
EPS bridge
201.00 → 313.00
Residual
-24.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.